autologous blood and marrow transplantation - Blog Science ...

Prince et al.
Table 1. High-dose regimens (planned three cycles)
Regimens
MT
Melphalan
Thiotepa
ITP (Phase I study)
307
Dose/cycle Patients (n) Total cycles delivered
100 mg/m 2
200 mg/m 2
2 6
Ifosfamide 10-12.5 g/m 2 23 59
Thiotepa
Paclitaxel
200-350 mg/m 2
175 mg/m 2
ITP with Isolex300i CD34 selection
Ifosfamide 10 g/m 2 14* 36
Thiotepa
Paclitaxel
CTP
Cyclophosphamide
Thiotepa
Paclitaxel
300 mg/m 2
175 mg/m 2
4 g/m 2
350 mg/m 2
175 mg/m 2
3 8
Total 42 109
*Eight underwent CD34 selection.
ifosfamide/mesna infusion, mesna (20% wt/wt of the ifosfamide dose) was
administered intravenously over 8 hours. Thiotepa was administered in equally
divided doses on days -4, -3, and -2. Paclitaxel (175 mg/m 2
) was administered as
a 3-hour infusion on day -2. Cryopreserved PBPC were thawed and infused on day
0. All patients received recombinant human (rh)G-CSF (filgrastim; Neupogen,
Amgen Australasia, Sydney, Australia) (5 pg/kg/d) subcutaneously from day 1
until the ANC was >1.5X10 9
/L for 3 consecutive days. All patients received
prophylactic ciprofloxacin, acyclovir, and ranitidine. The MTD was defined when
two or more patients developed National Cancer Institute (NCI) grade 4 nonhematologic
toxicity (excluding alopecia) or grade 3 neurologic, cardiac, or renal
toxicity or when two or more patients were unable to receive further high-dose
therapy because of hematologic toxicity.
Phase II Isolex300i CD34-selection study (n=14). To date, 14 patients have
been enrolled in a phase II study involving CD34-selection of PBPCs. Briefly, in
patients from whom >12X 10 6
/kg CD34 +
cells were obtained on a single day or on
two consecutive days of collections (n=8), cells underwent CD34 +
paramagnetic
selection using the Isolex300i (Baxter Healthcare, Irvine, CA). After selection, the
cells were divided and cryopreserved in the same way as described above. The total
volume of CD34-selected cells infused following each cycle was 20 mL. A